Is Wegovy an appetite suppressant — and is that the whole story?

Step 1: what GLP-1 receptors actually do to hunger

Glucagon-like peptide-1 (GLP-1) is a hormone your gut produces naturally after you eat. It travels to the brain (specifically to areas involved in appetite regulation) and signals that food has arrived. Semaglutide mimics this hormone, but lasts far longer than the version your body makes. The result is that those "I need to eat" signals are quieter and less urgent for much of the week.

This is why people on Wegovy often describe finding it easier to stop eating when they are satisfied rather than when the plate is empty. It is not a matter of willpower. The biological drive to keep eating is simply less insistent. How strongly Wegovy suppresses appetite varies from person to person, which is part of why clinical oversight matters throughout treatment.

The NHS patient information for semaglutide explains the mechanism clearly and is worth reading alongside your prescriber's guidance. What it also makes clear is that Wegovy works best alongside a reduced-calorie diet and increased physical activity, the medicine shifts the biology; the lifestyle choices determine how far that shift goes.

Step 2: the stomach, why fullness lasts longer on Wegovy

Alongside its effect on appetite centres in the brain, semaglutide slows gastric emptying. Food stays in your stomach longer than it ordinarily would, which extends the physical sensation of being full after a meal. This is separate from the brain effect and compounds it.

In practical terms, many people find they are satisfied with noticeably smaller portions. Some find their interest in food changes more broadly, not just eating less at mealtimes but thinking about food less between them. That shift in food preoccupation is one reason whether Wegovy is only an appetite suppressant is worth examining more carefully: the changes in how food feels rewarding go beyond a simple on/off hunger switch.

Knowing what to eat while this is happening matters. Protein intake, hydration and fibre all become more important when appetite is reduced, because eating less can mean eating fewer nutrients if you are not thoughtful about it. What to eat on Wegovy covers this in more detail, and your prescriber can refer you to dietary support if helpful.

Step 3: what the trial evidence tells us, and what it does not

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and found that participants using semaglutide 2.4mg alongside lifestyle support lost an average of around 15% of body weight, compared with around 2.4% in the placebo group. Those are meaningful differences.

What the trial cannot tell you is exactly how much of that weight loss came from reduced appetite alone versus the slower gastric emptying, the reduced food reward response, or simply the structure of being in a supervised programme. In practice, these mechanisms work together. Calling Wegovy just an appetite suppressant is a bit like calling a car just a fuel burner, technically one part of the truth, but not the whole picture.

If you are finding that Wegovy is not suppressing your appetite in the way you expected, that is a conversation to have with your prescriber. Dose, timing and individual variation all play a role. If appetite suppression has stopped or never arrived, the page on no appetite suppression on Wegovy covers the common reasons and what to do.

What Wegovy is (and is not) licensed for in the UK

NICE recommends semaglutide (Wegovy) for weight management in adults with a BMI of 35 or above and at least one weight-related condition, when used within a specialist service for a maximum of two years. Private prescribing follows the licensed criteria: BMI of 30 or above, or 27 or above with a qualifying condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

It is worth being clear on one thing: Wegovy is not licensed as a cosmetic or quick-fix intervention. The MHRA has stated that GLP-1 medicines are not assessed for rapid or aesthetic weight loss. The licence is for weight management as a health intervention, in people for whom excess weight carries clinical risk.

Understanding how Wegovy works also helps frame cost. Wegovy prices in the UK vary by dose and provider, and context on what that price should include (clinical review, prescriptions, aftercare) matters when you are comparing options. At the end of a journey that starts with a free consultation, the medicine arrives with DPD tracking to your door in plain, unbranded packaging, the pen itself is pre-filled and ready to use from the fridge.

If you want to understand whether semaglutide could be clinically appropriate for you, check your eligibility with our prescribers, a GPhC-registered Independent Prescriber reviews every consultation the same day, not an algorithm.